Press release
ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the ALK+ NSCLC Pipeline. Dive into DelveInsight's comprehensive report today! @ ALK+ NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the ALK+ NSCLC Pipeline Report
* On 03 September 2025, Pfizer announced a study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
* On 29 August 2025, Nuvalent Inc. conducted a Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naive, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
* On 22 August 2025, Gilead Sciences organized a study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
* DelveInsight's ALK+ NSCLC Pipeline report depicts a robust space with 6+ active players working to develop 7+ pipeline therapies for ALK+ NSCLC treatment.
* The leading ALK+ NSCLC Companies such as Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical and others.
* Promising ALK+ NSCLC Pipeline Therapies such as Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others.
Stay ahead with the most recent pipeline outlook for ALK+ NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ ALK+ NSCLC Treatment Drugs [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ALK+ NSCLC Emerging Drugs Profile
* SY-3505: Shouyao Holdings
Ficonalkib (SY-3505) is a highly potent, adenosine triphosphate-competitive, CNS-penetrant, 3rd-gen ALK TKI. In vitro kinase assay revealed that ficonalkib exhibits potent inhibition against both wild-type ALK and a diverse spectrum of mutants observed in patients resistant to 1st- and 2nd-gen ALK TKI, including L1196M, G1202R, F1174L, G1269S, and R1275Q20. The drug exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK). The drug is currently being evaluated under Phase III clinical trials for the NSCLC Treatment
* APG-2449: Ascentage Pharma
APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development. The updated results at the ASCO indicated favorable safety and promising antitumor activity in NSCLC Patients, and the preliminary efficacy observed in patients who were resistant to second-generation ALK inhibitors was particularly encouraging. APG-2449 is currently being evaluated in Phase I Non-Small Cell Lung Cancer Clinical Trials.
The ALK+ NSCLC Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of ALK+ NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ALK+ NSCLC Treatment.
* ALK+ NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* ALK+ NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ALK+ NSCLC market
Explore groundbreaking therapies and clinical trials in the ALK+ NSCLC Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New ALK+ NSCLC Drugs [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ALK+ NSCLC Companies
Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical and others.
ALK-positive Non-Small Cell Lung Cancer Ppeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
ALK+ NSCLC Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of ALK+ NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ ALK+ NSCLC Market Drivers and Barriers [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the ALK+ NSCLC Pipeline Report
* Coverage- Global
* ALK+ NSCLC Companies- Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical and others.
* ALK+ NSCLC Pipeline Therapies- Lorlatinib, XZP-3621, X-396 (ensartinib), Crizotinib, WX-0593, SAF-189s, and others.
* ALK+ NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ALK+ NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on ALK+ NSCLC Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ ALK+ NSCLC Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* ALK Positive Non-Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* ALK Positive Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* SY-3505: Shouyao Holdings
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* APG-2449: Ascentage Pharma
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* ALK Positive Non-Small Cell Lung Cancer - Collaborations Assessment- Licensing / Partnering / Funding
* ALK Positive Non-Small Cell Lung Cancer - Unmet Needs
* ALK Positive Non-Small Cell Lung Cancer - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alk-nsclc-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4168819 • Views: …
More Releases from ABNewswire
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmac …
DelveInsight's, "Prostate Cancer - Pipeline Insight, 2025," report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Prostate Cancer pipeline companies are Silenseed LTD, Lantheus, Pantarhei Oncology,…
Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical Trial Studies, EMA …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Amyotrophic…
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA A …
DelveInsight's, "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for ALK
ALK ELISA Kits Market Outlook and Future Projections for 2030
The alk elisa kits market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
ALK-1 Antibody Market Outlook and Future Projections for 2030
The alk-1 antibody market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the current…
ALK-positive Non-Small Cell Lung Cancer Pipeline: Companies Advancing Targeted T …
The therapeutic landscape for ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC), a genetically defined subset of lung cancer driven by ALK gene rearrangements, is undergoing a significant transformation. Biopharmaceutical companies are shifting focus from traditional chemotherapy to precision medicine approaches that directly inhibit ALK-driven oncogenic signaling. With multiple generations of ALK inhibitors now available and resistance mechanisms emerging, the spotlight is on next-generation inhibitors, combination regimens, and CNS-penetrant therapies designed…
Allergy Shots Market | ALK Abello, Aimmune Therapeutics, Allergy Therapeutics, A …
The global allergy shots market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the allergy shots market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Analysis By Major Manufa …
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones…
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market 2023: Analysis By Regional Outl …
Los Angeles, United State: The latest report published by QY Research presents a thorough analysis of the global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market. The research report evaluates the ever-changing market dynamics that are expected to impact the trajectory of the overall market. Analysts studied the historical achievements of the market and compared it to the current market trends, to chart the trajectory. For a detailed discussion about the global ALK Tyrosine…
